Buy Amphastar

Logo for stock AMPH (Amphastar)

Amount

£
GBP

Latest price

$25.12
(£1.00 = $1.33)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$1.193B

P/E ratio

8.20

EPS

$3.064

Beta

0.77

Dividend rate

N/A

Dividend yield

N/A

About

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

CEO

Dr. Yongfeng (Jack) Zhang, Ph.D.

Employees

2,028

Sector

Health

Company HQ

RANCHO CUCAMONGA, United States of America

News

Logo for news article #0 (Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock?)

Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock?

Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.

Zacks Investment Research

May 01, 2025

Logo for news article #1 (Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025)

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Accesswire

April 30, 2025

Logo for news article #2 (Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference)

Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.

Accesswire

April 03, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.